Becton Dickinson and Company (NYSE:BDX), a leading global medical technology firm, is gearing up to release its quarterly earnings on August 7, 2025. BDX specializes in the development and sale of medical devices, instrument systems, and reagents, operating through three main segments: BD Medical, BD Life Sciences, and BD Interventional. The company competes with healthcare giants like Medtronic and Johnson & Johnson.
Wall Street's expectations for BDX's quarterly earnings include an EPS of $3.42 and revenue projections of around $5.5 billion. The anticipated revenue for this quarter is $5.48 billion, reflecting a 9.9% increase from the previous year. However, the EPS is expected to see a slight decline of 2.3%, according to Zacks.
The BD Medical segment is poised for a notable growth of 17.7%, propelled by the introduction of new products like the HemoSphere Alta and BD neXus. Additionally, the BD Interventional segment is expected to witness a 2.9% sales increase, buoyed by sustained demand and the launch of the Phasix ST hernia patch. These developments are pivotal for BDX's strategic growth.
In the preceding quarter, BDX reported an EPS of $3.35, surpassing the Zacks Consensus Estimate by 2.1%. Over the last four quarters, BDX has consistently beaten the Zacks Consensus Estimate, achieving an average earnings surprise of 6%. Investors are eagerly awaiting to see if BDX can continue this trend in the forthcoming earnings announcement.
BDX's financial metrics, including a price-to-earnings (P/E) ratio of 34.06 and a price-to-sales ratio of 2.43, alongside a debt-to-equity ratio of 0.76, offer insights into the company's market valuation and financial health, aiding investors in gauging BDX's potential for future growth.
